Typical and atypical antipsychotics: Is there a difference in their influence on neurocognition?;Typische en atypische antipsychotica bij patiënten met schizofrenie: Is er verschil in invloed op neurocognitie?

Tijdschrift voor Psychiatrie

Volumn 53, Issue 2, 2011, Pages 107-117

  Faber, G ^a   Van Gool, A R ^b   Smid, H G O M ^c   Wiersma, D ^c   Van Den Bosch, R J ^c  

^a Yulius Mental Health Institute   (Netherlands)

^b Yulius Academie te Dordrecht   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Antipsychotics; Neurocognition; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

COGNITION; COGNITIVE DEFECT; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; HUMAN; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; HUMANS; NEUROPSYCHOLOGICAL TESTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 79951967487     PISSN: 03037339     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Ahn YM, Lee KY, Kim C-E, Kim J-J, Kang D-Y, Jun T-Y, e.a. Changes in neurocognitive function in patients with schizophrenia after starting or switching to amisulpride in comparison with the normal controls. J Clin Psychopharmacol 2009; 29: 117-23.
2. Akdede BBK, Yagcioglu AEA, Alptekin K, Turgut TI, Tümüklü M, Yaziki MK, e.a. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. J Clin Psychiatry 2006; 67: 1912-9. (Pubitemid 46048188)
3. Aleman A, Hijman R, de Haan EHF, Kahn RS. Memory impairment in schizophrenia: a meta-analysis. Am J Psychiatry 1999; 156: 1358-66.
4. Barker MJ, Greenwood KM, Jackson M, Crow SF. Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Arch Clin Neuropsychol 2004; 19: 437-54. (Pubitemid 38373546)
5. Bowie CR, Leung WW, Reichenberg A, McClure MM, Patterson TL, Heaton RK, e.a. Predicting schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures. Biol Psychiatry 2008; 63: 505-11.
6. Buchanan RW, Davis M, Goff D, Green MF, Keefe RS, Leon AC, e.a. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull 2005; 31: 5-19.
7. Carpenter WT, Gold JM. Another view of therapy for cognition in schizophrenia. Biol Psychiatry 2002; 52: 969-72.
8. Carpenter WT, Koenig JI. The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology 2008; 33: 2061-79. (Pubitemid 351992095)
9. Crespo-Facorro B, Rodriguez-Sanchez JM, Perez-Iglesias R, Mata I, Ayesa R, Ramirez-Bonilla M, e.a. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. J Clin Psychiatry 2009; 70: 717-29.
10. Cuesta M, Garcia de Leon E, Campos MS, Peralta V. Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis. Br J Psychiatry 2009; 194: 439-45.
11. Davidson M, Galderisi S, Weise M, Werbeloff N, Fleischhacker WW, Keefe RS, e.a. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 2009; 166: 675-82.
12. Fagerlund B, Mackeprang T, Gade A, Hemmingsen R, Glenthøj BY. Effects of low-dose risperidone and low-dose zudopenthixol on cognitive functions in first-episode drug-naive schizophrenic patients. CNS Spectr 2004; 19: 364-74. (Pubitemid 38649725)
13. Gallhofer B, Jaanson P, Mittoux A, Tanghøj P, Lis S, Krieger S. Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol. Pharmacopsychiatry 2007; 40: 1-12.
14. Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC, e.a. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia. Is it a practice effect? Arch Gen Psychiatry 2007; 64: 1115-22.
15. Gonzalez-Blanch C, Perez-Iglesias R, Pardo-Garcia G, Rodriguez-Sanchez JM, Martinez-Garcia O, Vazquez-Barquero JL, e.a. Prognostic value of cognitive functioning for global functional recovery in first-episode schizophrenia. Psychol Med 2009; Epub Ahead of print. doi:10.1017/S0033291709991267
16. Green MF, Kern, RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 2004; 72: 41-51. (Pubitemid 39452904)
17. Gurpegui M, Alvarez E, Bousono M, Ciudad A, Gomez JC, Olivaress JM. Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms. Eur Neuropsychopharmacol 2007; 17: 725-34. (Pubitemid 47419294)
18. Harvey PD, Keefe RSE. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001; 158: 176-84. (Pubitemid 32116511)
19. Harvey PD, Rabinowitz J, Eerdekens M, Davidson M. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry 2005; 162: 1888-95. (Pubitemid 41428618)
20. Harvey PD, Bowie CR, Loebel A. Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-bind comparison of ziprasidone vs. olanzapine. J Neuropsychiatry Clin Neurosci 2006; 18: 54-63. (Pubitemid 43277257)
21. Harvey PD, Sacchetti E, Galluzzo A, Romeo F, Gorini B, Bilder RM, e.a. A randomized double-blind comparison of ziprasidone vs. clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment. Schizophr Res 2008; 105: 138-43.
22. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998; 12: 426-45. (Pubitemid 28323862)
23. Holthausen EAE, Wiersma D, Cahn W, Kahn RS, Dingemans PM, Schene AH e.a. Predictive value of cognition for different domains of outcome in recent-onset schizophrenia. Psychiatry Res 2007; 149: 71-80.
24. Honer WG, Thornton AE, Chen EYH, Chan RCK, Wong JOY, Bergmann A, e.a. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006; 354: 472-82. (Pubitemid 43200298)
25. Jann MW. Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis. Pharmacotherapy 2004; 24: 1759-83. (Pubitemid 39578963)
26. Keefe RS. Cognitive deficits in patients with schizophrenia: effects and treatment. J Clin Psychiatry 2007; 68(suppl. 14): 8-13.
27. Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizopht Bull 1999; 25: 201-22. (Pubitemid 29272501)
28. Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, e.a. Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biol Psychiatry 2006a; 59: 97-105.
29. Keefe RS, Young CA, Rock SL, Purdon SE, Gold JM, Breier A. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidon, and haloperidol in schizophrenia. Schizophr Res 2006b; 81: 1-15.
30. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM e.a. Neurocognitive effects of antipsychotic medication in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 2007a; 64: 633-47.
31. Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP e.a. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007b; 164: 1061-71. (Pubitemid 47121395)
32. Kern RS, Green MF, Cornblatt BA, Owen JR, McQuade RD, Carson WH, e.a. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology 2006; 187: 312-20.
33. Krakowski M, Czobor P, Nolan KA. Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. J Clin Psychopharmacol 2008; 28: 485-93.
34. Lee S-M, Chou Y-H, Li M-H, Wan F-J, Yen M-H. Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1101-7. (Pubitemid 46824021)
35. Lindenmayer J-P, Khan A, Iskander A, Abad MT, Parker B. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. J Clin Psychiatry 2007; 68: 368-79. (Pubitemid 46506800)
36. Mesholam-Gately RI, Giuliano AJ, Goff KP, Faraone SV, Seidman LJ. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 2009; 23: 315-36.
37. Milev P, Ho B-C, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 2005; 162: 495-506. (Pubitemid 40343916)
38. Minzenberg MJ, Poole JH, Benton C, Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry 2004; 161: 116-24. (Pubitemid 38419316)
39. Mishara AL, Goldberg TE. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry 2004; 55: 1013-22. (Pubitemid 38581917)
40. Mortimer AM, Joyce E, Balasubramaniam K, Choudhary PC, Saleem PT. Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia. Hum Psychopharmacol 2007; 22: 445-54. (Pubitemid 47611299)
41. Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, e.a. The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity. Am J Psychiatry 2008; 165: 203-13. (Pubitemid 351704520)
42. Remillard S, Pourcher E, Cohen H. The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study. Schizophr Res 2005; 80: 99-106 (Pubitemid 41587467)
43. Riedel M, Müller N, Spellmann I, Engel RR, Musil R, Valdevit R, e.a. Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia. Eur Arch Psychiatry Clin Neurosci 2007; 257: 402-12.
44. Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 2004; 161: 473-9. (Pubitemid 38326102)
45. Terry AV, Gearhart DA, Warner S, Hohnadel EJ, Middlemore M-L, Zhang G, e.a. Protracted effects of chronic oral haloperidol and risperidone on nerve growth factor, cholinergic neurons, and spatial reference learning in rats. Neuroscience 2007; 150: 413-24.
46. Thornton AE, Van Snellenberg JX, Sepehry AA, Honer WG. The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review. J Psychopharmacol 2006; 20: 335-46.
47. Velligan DI, Bow-Thomas CC, Mahurin RK, Miller AL, Halgunseth LC. Do specific neurocognitive deficits predict specific domains of community function in schizophrenia? J Nerv Ment Dis 2000; 188: 518-24.
48. Voruganti LP, Awad AG, Parker G, Forrest C, Usmani Y, Fernando MLD, e.a. Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine. Schizophr Res 2007; 96: 146-55.
49. Wagner M, Quednow BB, Westheide J, Schlaepfer TE, Maier W, Kühn K-U. Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride. Neuropsychopharmacology 2005; 30: 381-90. (Pubitemid 40129489)
50. Weiss EM, Bilder RM, Fleischhacker WW. The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia. Psychopharmacology 2002; 162: 11-7. (Pubitemid 34639550)
51. Werkgroep Schizofrenie. Multidisciplinaire richtlijn schizofrenie. Utrecht: Kwaliteitsinstituut voor de Gezondheidszorg CBO & Trimbos-instituut 2005. http://www.ggzrichtlijnen.nl
52. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005; 8: 457-72. (Pubitemid 41002500)
53. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res 2007; 89: 211-24. (Pubitemid 44881296)
54. Zhong KX, Sweitzer DE, Hamer RM, Lieberman JA. Comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, double-blind, flexible-dose, 8-week study. J Clin Psychiatry 2006; 67: 1093-103. (Pubitemid 44230881)